Skip to Main Content

Department of Pathology

The Department of Pathology at Yale, one of the first departments organized at Yale School of Medicine, is dedicated to continuing its long and distinguished tradition of world-renowned clinical care, cutting-edge scientific research, and rigorous training of the next generation of pathologists to be leaders in their field. With robust research investigations, teaching programs and exceptional clinical patient care, we are able to bring new knowledge and innovative therapeutic approaches to our patients and to medicine. Our dedication to excellence in both the clinical and the academic arenas is paramount to our mission as a Department and to our goal of advancing patient care through expert diagnostics and novel therapeutics.


New treatment path discovered at Yale for rare form of rickets

Demetrios Braddock, MD, PhD

A new study from a team of clinicians and investigators from Yale and other institutions compared the response of patients with a severe form of rickets called ARHR2 treated with conventional therapy to that of mice treated with an enzyme replacement therapy. The replacement therapy was developed by Dr. Demetrios Braddock, Associate Professor of Pathology. The investigators found that while conventional therapy improved the rickets in ARHR2, it did not correct the underlying osteoporosis and also predisposed patients to increased renal calcifications. The finding was particularly worrisome in adolescents with the disease known to develop debilitating calcifications in their joints, arteries, and cardiovascular system as they entered early adulthood. In contrast, adding the enzyme therapy to the conventional therapy in a mouse model of ARHR2 eliminated histologic evidence of rickets, led to bigger and stronger bones, and eliminated the risk of increased renal calcifications induced by the conventional therapy. The study was published in the Jan. 19 edition of the Journal of Bone and Mineral Research.

ARHR2 is a rare but devastating disease resulting from deficiency in an enzyme called ‘ENPP1’ which regulates tissue mineralization. Half of the children born with homozygous ENPP1 deficiency will die within the first 6 months of life due to cardiac calcifications in a disease phase known as ‘Generalized Arterial Calcification of Infancy’ (GACI). The children who survive GACI may stabilize and improve, but soon develop a severe bone wasting disease due to elevation of a hormone called FGF23 which induces a phosphate wasting rickets called ‘Autosomal Recessive Hypophosphatemic Rickets Type-2’ (ARHR2). The phosphate wasting in ARHR2 is currently treated with phosphate replacement. While the treatment does improve the rickets, Braddock and his team were concerned that giving phosphate to patients predisposed to tissue calcification could pose risks to ARHR2 patients. They reached out to clinicians at the National Institutes of Health and the University of Hamburg who were treating these patients for additional information on the treatment response.

Braddock said: “The study could not have been performed without the close collaboration and involvement of the dedicated physicians treating patients with this severe disease. Their concern for their patients was evident in their enthusiasm and willingness to share their experiences and frustrations with us as we investigate alternative therapies to better address the disease pathogenesis.”

access Journal article here

Researchers Develop a Mice Model to Identify and Study the Vascular Dynamics of CCM Lesions Leading to Cerebral Hemorrhage, Strokes, and Seizures

Huanjiao Jenny Zhou, MD, PhD

Yale researcher Huanjiao Jenny Zhou (Pathology) and additional School of Medicine researchers have established a Cerebral Cavernous Malformations (“CCM”) mice model which “identifies and uncovers the mechanism in which CCM3 mutation induced caveolae-Tie2 signaling contributes to CCM pathogenesis.”

Cerebral cavernous malformations (CCMs) are “vascular abnormalities which primarily occur in adulthood and lead to cerebral hemorrhage, stroke, and seizures.” CCMs can be initiated by an “endothelial cell (EC) loss of any one of the three Ccm genes: CCM1 (KRIT1), CCM2 (OSM), or CCM3 (PDCD10).”

Dr. Zhou and her research colleagues utilize mice “with a brain EC-specific deletion of Pdcd10 (Pdcd10BECKO)” which typically survive between 6-12 months. During this period, the mice develop bona fide CCM lesions in all regions of their brain which allowed the research team to study the “vascular dynamics of CCM lesions by using transcranial two-photon microscopy.”

These researchers have not only created a CCM mice model which studies vascular abnormalities, but they have also identified “caveolae-mediated Tie2 receptor signaling in the presence of its ligand Angpt2 which can offer a therapeutic approach to treat CCM disease.”

Other members of the Yale research team include: Lingfeng Qin, Quan Jiang, Haifeng Zhang, Busu Li, Qun Lin, her collaborators Katie N. Murray, Jaime Grutzendler and Wang Min in the Program of Vascular Biology and Therapeutics, Departments of Pathology, Neurobiology and Cell Biology You can read more about this exciting research in the January 25th  online edition of Nature Communications.

access journal article here

Yale and New Haven to begin saliva testing mini-program in New Haven learning hubs after fall term obstacles


After a months-long struggle, Yale researchers and New Haven officials are implementing a saliva testing program within some community spaces around the city, though not within New Haven’s public schools as researchers originally hoped. The Yale Pathology Lab will process the samples.

The testing program uses SalivaDx, an affordable and streamlined method of using saliva to test for the coronavirus that has gained national acclaim since its development at Yale. Yale researchers have secured grants and coordinated with the city to fund a testing program for adults working in some of the city’s learning hubs — spaces inside some city churches and recreation centers where small groups of students can take classes if they do not have internet, a safe and quiet environment or adequate nutrition at home.

The researchers developed SalivaDx to be an open-source, uncommercialized protocol, with no kit required, in an effort to make it accessible to labs across the country. They have extended the emergency use authorization to more than 96 labs in 35 different states.

read the full article in the Yale Daily

Cancer Research Awards presented to Ranjit Bindra and Don Nguyen

Ranjit Bindra, MD, PhD, Professor Therapeutic Radiology (left) and Don Nguyen, PhD, Associate Professor of Pathology and Medicine (Medical Oncology) (right).
The Class of 1961 Cancer Research Awards were presented to Ranjit Bindra, MD, PhD, Professor Therapeutic Radiology and Don Nguyen, PhD, Associate Professor of Pathology and Medicine (Medical Oncology). They were honored for their significant accomplishments in cancer research at Yale University as members of the faculty, coupled with the expectation for future outstanding contributions to the cause of cancer and the development of novel cancer treatments.

Yale Pathologist Dr. Harold Sanchez discusses how autopsies have changed during COVID-19

Dr. Harold Sanchez, Assistant Professor in the Department of Pathology at Yale School of Medicine and a Pathologist for Yale Medicine, appeared on WTNH News 8 to tell about autopsies and what can be learned from them during the COVID-19 pandemic. He discusses how autopsies have changed during the pandemic and what role autopsies have had in giving doctors a better understanding of the damage that the virus can do.

View the video on [3:45 minutes]